Core Viewpoint - The company, Lanfeng Biochemical, addressed investor inquiries on October 29, stating that its operational status can be found in the periodic reports disclosed by the company [2] Summary by Relevant Sections - **Company Operations** - Lanfeng Biochemical confirmed that detailed information regarding its operational performance is available in the periodic reports it has released [2]

Group 1 - The company, Jiangsu Lanfeng Biological Chemical Co., Ltd., has completed the registration change and received a new business license following a reduction in registered capital and amendments to its articles of association [2][3]. - The registered capital after the change is 355.563978 million yuan [2]. - The company operates in various sectors including the production and sale of pesticides, chemical products, and renewable energy technologies [2]. Group 2 - The company held its seventh board meeting and the first extraordinary shareholders' meeting in 2025 to approve the capital reduction and related amendments [2]. - The new business license includes updated information such as the unified social credit code and the legal representative [2]. - The company is involved in the import of raw materials and machinery necessary for its production and research activities [2].

Core Viewpoint - Recently, the company completed the registration capital change and related business registration changes, obtaining a new business license from the Xuzhou Municipal Administration of Government Services [1] Group 1 - The company is Bluefeng Biochemical (002513) [1] - The announcement was made on the evening of October 27 [1] - The company has updated its articles of association as part of the registration process [1]

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-067 江苏蓝丰生物化工股份有限公司 近日，公司完成了注册资本变更及《公司章程》备案相关工商登记变更手续， 并取得了徐州市政务服务管理办公室换发的《营业执照》，变更后营业执照内容 如下： 名称：江苏蓝丰生物化工股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 一、基本情况 类型：股份有限公司（上市） 二、完成工商变更登记情况 住所：江苏新沂经济开发区宁夏路 2 号 法定代表人：李质磊 江苏蓝丰生物化工股份有限公司（以下简称"公司"）分别于 2025 年 7 月 28 日、2025 年 8 月 15 日召开第七届董事会第二十四次会议、2025 年第一次临 时股东会审议通过了《关于减少注册资本、修订<公司章程>并办理工商登记的议 案 》 。 具 体 内 容 详 见 公 司 刊 登 在 指 定 信 息 披 露 网 站 巨 潮 资 讯 网 （www.cninfo.com.cn）及《上海证券报》、《证券时报》、《中国证券报》上 的《关于减少注册资本、修订< ...

Core Viewpoint - The stock of Jiangsu Lanfeng Bio-chemical Co., Ltd. has shown significant growth this year, with a year-to-date increase of 97.32%, indicating strong market interest and performance in the agricultural chemicals sector [1][2]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 1.83 billion yuan, representing a year-on-year growth of 28.26% [2]. - The net profit attributable to shareholders was -77.18 million yuan, showing a year-on-year increase of 58.29% despite being negative [2]. Stock Market Activity - As of October 27, the stock price reached 8.84 yuan per share, with a trading volume of 319 million yuan and a turnover rate of 13.96% [1]. - The stock has appeared on the daily trading leaderboard 15 times this year, with the most recent appearance on October 23, where it recorded a net buy of -50.62 million yuan [1]. Shareholder Information - As of September 30, the number of shareholders increased to 41,700, a rise of 48.71% from the previous period, while the average circulating shares per person decreased by 32.41% to 6,360 shares [2]. Business Segments - The company's main business segments include battery cells (43.84%), components (31.70%), pesticide raw materials and formulations (17.20%), and sulfur (4.09%) [2].

Core Viewpoint - Bluefeng Biochemical (002513.SZ) reported a revenue of 1.83 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 28.26%. However, the company recorded a net loss attributable to shareholders of 77.18 million yuan, with a net loss of 79.47 million yuan after excluding non-recurring gains and losses [1] Financial Performance - The company achieved an operating income of 1.83 billion yuan in the first three quarters of 2025 [1] - Year-on-year revenue growth was reported at 28.26% [1] - The net loss attributable to shareholders was 77.18 million yuan [1] - The net loss after excluding non-recurring gains and losses was 79.47 million yuan [1]

Group 1 - The core point of the article is that Lanfeng Biochemical (SZ 002513) held its 28th meeting of the 7th board of directors on October 24, 2025, via telecommunication, where it reviewed the proposal for the third extraordinary shareholders' meeting of 2025 [1] - For the first half of 2025, Lanfeng Biochemical's revenue composition was 77.39% from photovoltaic products and 22.61% from pesticides [1] - As of the time of reporting, Lanfeng Biochemical had a market capitalization of 3.1 billion yuan [1] Group 2 - The article mentions that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year, highlighting the hot secondary market in biomedicine [1] - A dialogue with Lu Gang, a partner at Chuangdong Investment, indicates that while the secondary market is thriving, the primary market is facing challenges in fundraising [1]

滁州鼎卓会计师事务所（普通合伙) 安徽旭合新能源科技有限公司 2025年1-6 月期间报表审计报告 鼎卓会审字[2025]第 075 号 安徽旭合新能源科技有限公司全体股东: 一、审计意见 我们审计了安徽旭合新能源科技有限公司(以下简称"安徽旭合")财务报表, 包括 2025 年 6 月 30 日的合并及公司资产负债表，2025 年 1-6 月的合并及公司 利润表、合并及公司现金流量表、合并及公司所有者权益变动表以及相关财务报 表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制, 公允反映了安徽旭合 2025 年 6 月 30 日的合并及公司财务状况以及 2025 年 1-6 月的合并及公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注 册会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。 按照中国注册会计师职业道德守则,我们独立来要徽旭合,铁赓行了职业道德方 面的其他责任。我们相信,我们获取的审批 当的,为发表审计意 亚游戏 见提供了基础。 我们的目标是对财务报表整体是否不存在由于舞弊或错误导致的重大 ...

Core Insights - The company reported a third-quarter revenue of 634 million yuan, representing a year-on-year increase of 9.69% [1] - The net profit for the third quarter showed a loss of 32.4 million yuan, a decline of 29.04% [1] - For the first three quarters, the company achieved a revenue of 1.83 billion yuan, reflecting a year-on-year growth of 28.26% [1] - The net profit for the first three quarters recorded a loss of 77.18 million yuan, which is a decrease of 58.29% [1]

证券代码：002513 证券简称：蓝丰生化 公告编号：2025-063 江苏蓝丰生物化工股份有限公司 关于放弃控股子公司优先认缴权暨关联交易的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 一、放弃优先认缴权暨关联交易概述 本次增资完成后，公司持有旭合科技的股权比例将由增资前的 49.2449%变更 为 46.7810%，旭合科技仍为公司控股子公司，不涉及合并报表范围的变更。 二、关联关系情况和关联方基本情况 1、关联关系情况 鉴于公司董事长、实际控制人郑旭先生是旭合科技的实际控制人；公司董事、 总经理李质磊先生是旭合科技股东巽顺投资及瓴先投资的执行事务合伙人；公司 副董事长崔海峰先生、董事路忠林先生是旭合科技股东巽顺投资及瓴先投资的有 限合伙人。因此根据《深圳证券交易所股票上市规则》及《深圳证券交易所上市 公司自律监管指引第 7 号——交易与关联交易》等相关规定，本次事项构成关联 1 交易。 2、关联方基本情况 郑旭先生，1965 年出生，中国国籍，无境外永久居留权，本科学历，工商管 理专业，高级经济师。郑旭及其一致行动人巽顺投资合计持有公司 96,05 ...